The excellent anti-tumour strategy (CTGVT, OV-gene) and the excellent anti-tumor gene (IL-24)

International Journal of Biomedical Science

Volumn 8, Issue 2, 2012, Pages 87-93

  Liu, Xin Yuan ^a,b  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 24; LONTUCIREV; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

CANCER GENE THERAPY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; REVIEW; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 84865385753     PISSN: 15509702     EISSN: 15552810     Source Type: Journal    
DOI: None     Document Type: Review

References (3)

1. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 2005; 16: 1016-1027.
2. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst. 2006; 98: 298-300.
3. Liu XY. Genetic and Virological Therapy of Cancer (Chinese: A New Anticancer Strategy